Titan Pharmaceuticals

TTNP · NASDAQ

$4.61−$0.18 (−3.76%)TodayMarket closed ·
No price history for this range.

Key indicators

TTNP profitability and balance sheet ratios

EPS -$0.8643 in Q4 FY24, against -$2.61 a year earlier.

EPS by quarter
PeriodEPS
Q1 FY23-$2.23
Q2 FY23-$2.11
Q3 FY23-$0.4501
Q4 FY23-$2.61
Q1 FY24-$1.24
Q2 FY24-$2.29
Q3 FY24-$0.8348
Q4 FY24-$0.8643

Where the money went

Q3 FY23, from revenue to net income

Titan Pharmaceuticals brought in $0.0M of revenue in Q3 FY23, −95.8% on a year earlier. It made a net loss of $0.3M.

Revenue
$0.0M
Costs, expenses and taxes
$0.3M
Net income
−$0.3M
Net margin
-8450.0%

Income statement

Revenue and profit by reporting period

Revenue
Net income
TTNP income statement, quarterly
Line itemQ4 FY24Q1 FY25Q2 FY25
Revenue$0.0M$0.0M$0.0M
Gross profit$0.0M$0.0M$0.0M
Operating income−$0.7M−$0.5M−$0.7M
Net income−$0.8M−$0.6M−$0.7M
Diluted EPS-$0.86-$0.62-$0.65

Balance sheet

What the company owns and owes at period end

Total assets
Total liabilities
TTNP balance sheet, quarterly
Line itemDec 2024Mar 2025Jun 2025
Total assets$2.9M$2.2M$3.1M
Total liabilities$0.5M$0.3M$0.3M
Shareholder equity$2.4M$1.9M$2.8M
Cash and short-term investments$2.8M$1.9M$2.8M
Total debt$0.0M$0.0M$0.0M

Cash flow

Cash in and out from operations, investing and financing

Operating
Investing
Financing
TTNP cash flow, quarterly
Line itemQ4 FY24Q1 FY25Q2 FY25
Operating cash flow−$0.5M−$0.9M−$0.7M
Investing cash flow$0.0M$0.0M$0.0M
Financing cash flow−$0.1M−$0.0M$1.5M
Capital expenditure$0.0M$0.0M$0.0M
Free cash flow−$0.5M−$0.9M−$0.7M

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.